Background: Allergic Rhinitis and its Impact on Asthma (ARIA) differentiates mild from moderate/severe patients on the basis of 4 severity items. The high prevalence of moderate/severe patients suggests the need to differentiate between them.
Objectives: To identify the categorization that maximizes discrimination between moderate and severe allergic rhinitis (AR) by using ARIA guidelines.
Methods: Observational, cross-sectional study. Clinical characteristics, nasal symptoms (Total Symptom Score 4), and health-related quality of life (HRQL; Rhinoconjunctivitis Quality of Life Questionnaire and Short Form 12) were assessed. The association of severity items (sleep, daily activities/sport, work/school, and troublesome symptoms) with symptoms and HRQL was analyzed using linear regression models. ANOVA and effect sizes were used to assess differences in symptoms and HRQL among groups defined by the number of affected ARIA items.
Results: Nontreated patients (N = 141) with moderate/severe AR were studied. All severity items showed a similar independent association with symptoms and HRQL scores, and there were no interaction effects, indicating that categorization of patients into moderate and severe could be based only on the number of items affected. Effect sizes were highest between patients with 4 affected ARIA items and those with 3, 2, or 1 affected item (effect sizes greater than 0.8 in all comparisons using Rhinoconjunctivitis Quality of Life Questionnaire and Short Form 12 Physical Composite Summary, and greater than 0.5 using the Total Symptom Score 4; P < .001).
Conclusion: Using ARIA severity items, the criterion that best discriminates AR severity is considering moderate those with 1 to 3 affected items and severe those with 4.
Clinical Implications: Discrimination between patients with moderate and severe AR should help to obtain homogeneous populations for both research and clinical purposes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2007.04.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum Periostin as a Potential Biomarker in the Evaluation of Allergic Rhinitis: A Pilot Study.
J Asthma Allergy
January 2025
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
Purpose: Although periostin has recently emerged as a new mediator in chronic allergic diseases, particularly in upper airway disease, its significance as a biomarker for allergic rhinitis (AR) is still unclear. Therefore, we aimed to assess the potential of periostin as a novel candidate biomarker for diagnosing and assessing the severity of AR.
Patients And Methods: A total of 40 patients with AR and 22 healthy controls, all aged over 18 years, were recruited for the study.
Efficacy of Subcutaneous, Sublingual and Oral Immunotherapy for Allergens: A Comparative Study.
Immunology
January 2025
Department of Allergology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland.
The purpose of this study was to compare the efficacy and safety of subcutaneous, sublingual, oral specific immunotherapy in patients who suffer from allergic conditions to pollen from trees, grasses and weeds, house dust mites and Alternaria alternata spores. A literature search was performed separately for each type of allergen and each administration route of the drug. As a result, it was found that all administration routes were quite effective.
View Article and Find Full Text PDFMolecular dynamics simulations to decipher the hotspots at the allosteric site of human 5-lipoxygenase.
J Mol Graph Model
January 2025
Molecular Modeling and Protein Engineering Lab, Biology Division, Department of Humanities and Sciences, Indian Institute of Petroleum and Energy, Visakhapatnam, Andhra Pradesh, 530003, India. Electronic address:
Human 5-lipoxygenase (LOX) is a non-heme, Fe-containing LOX which catalyses the conversion of arachidonic acid (AA) to leukotriene A (LTA). LTA is subsequently converted to cysteinyl-LTs and LTB that cause bronchoconstriction and act as chemotactic and chemokinetic agent on human leukocytes, respectively. Leukotrienes play significant roles in inflammation in asthma, cardiovascular diseases, allergic rhinitis, atopic dermatitis, inflammatory bowel disease, rheumatoid arthritis, psoriasis and many more.
View Article and Find Full Text PDFIn-silico discovery of efficient second-generation drug derivatives with enhanced antihistamine potency and selectivity.
Comput Biol Chem
January 2025
Department of Chemistry, University of Agriculture Faisalabad, Faisalabad 38000, Pakistan.
The current study focuses on the potential of second-generation antihistamines, which exhibit fewer side effects compared to first-generation drugs, to block the Histamine H receptor (HR) and mitigate allergic responses. We screened several derivatives of second-generation drugs taking Desloratadine (Deslo) and Acrivastine (Acra) as seed compounds. We performed molecular docking, drug-likeness, quantum chemical calculations, UV-visible and infrared spectroscopy, molecular electrostatic potential (MEP) mapping for understanding drug derivatives potential as efficient drugs and molecular dynamics (MD).
View Article and Find Full Text PDFCMPK2 promotes NLRP3 inflammasome activation via mtDNA-STING pathway in house dust mite-induced allergic rhinitis.
Clin Transl Med
January 2025
Allergy Center, Department of Otolaryngology, Affiliated Eye and ENT Hospital, Fudan University, Shanghai, China.
Background: House dust mite (HDM) is the leading allergen for allergic rhinitis (AR). Although allergic sensitisation by inhaled allergens renders susceptible individuals prone to developing AR, the molecular mechanisms driving this process remain incompletely elucidated.
Objective: This study aimed to elucidate the molecular mechanisms underlying HDM-induced AR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!